vestibИзвестия Национальной академии наук Беларуси. Серия биологических наукProceedings of the National Academy of Sciences of Belarus, Biological Series1029-89402524-230XThe Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1029-8940-2021-66-3-357-369vestib-766Research ArticleОБЗОРЫREVIEWSВозможный ответ молекулярной биотехнологии на вызов SARS-CoV-2Possible response of molecular biotechnology to call SARS-CoV-2ЗинченкоА. И.ZinchenkoA. I.

Зинченко Анатолий Иванович - член-корреспондент, доктор биологических наук, профессор, заведующий лабораторией.

ул. Купревича, 2, 220141, Минск.

Anatoli I. Zinchenko - Corresponding Member, D. Sc. (Biol.), Professor, Head of the Laboratory, Institute of Microbiology of the National Academy of Sciences of Belarus.

2, Kuprevich Str., 220141, Minsk.

zinch@mbio.bas-net.byБиричевскаяЛ. Л.BirichevskayaL. L.

Биричевская Лариса Леонидовна - кандидат биологических наук, доцент, старший научный сотрудник.

ул. Купревича, 2, 220141, Минск.

Larisa L. Birichevskaya - Ph. D. (Biol.), Associate Professor, Senior Researcher, Institute of Microbiology of the National Academy of Sciences of Belarus.

2, Kuprevich Str., 220141, Minsk.

l.birichevskaya@mbio.bas-net.byКазловскийИ. С.KazlouskiI. S.

Казловский Илья Сергеевич - магистр биологических наук, научный сотрудник.

ул. Купревича, 2, 220141, Минск.

Illia S. Kazlouski - Master of Biol. Sci., Researcher, Institute of Microbiology of the National Academy of Sciences of Belarus.

2, Kuprevich Str., 220141, Minsk.

kazlouski.illia@gmail.comБулатовскийА. Б.BulatovskiA. B.

Булатовский Алексей Борисович - магистр биологических наук, младший научный сотрудник.

ул. Купревича, 2, 220141, Минск.

Aleksei B. Bulatovski - Master of Biol. Sci., Junior Researcher, Institute of Microbiology of the National Academy of Sciences of Belarus.

2, Kuprevich Str., 220141, Minsk.

a.bulatovski@yandex.ruИнститут микробиологии НАН БеларусиInstitute of Microbiology of the National Academy of Sciences of Belarus202104082021663357369Copyright © Зинченко А.И., Биричевская Л.Л., Казловский И.С., Булатовский А.Б., 20212021Зинченко А.И., Биричевская Л.Л., Казловский И.С., Булатовский А.Б.Zinchenko A.I., Birichevskaya L.L., Kazlouski I.S., Bulatovski A.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestibio.belnauka.by/jour/article/view/766

Пандемия COVID-19, вызванная коронавирусом SARS-CoV-2, затронула практически все стороны жизнедеятельности большинства стран и народов. B течение 2020 г. заболели COVID-19 порядка 100 млн жителей Земли, из которых 2 млн человек умерли. Поэтому фармацевтические компании многих стран включились в гонку по скорейшему созданию профилактических противовирусных вакцин. Однако не исключена вероятность, что парентеральные вакцины против быстро мутирующего пандемического коронавируса могут оказаться недостаточно эффективными, поскольку создаются без должной проверки на отдаленные побочные эффекты.

B качестве возможной альтернативы традиционному парентеральному вакцинированию в настоящей мини-обзорной статье рассматривается подход, предусматривающий кроме интраназальной адъювантной вакцинации фармакологическую инактивацию коронавируса с помощью рибо-фавипиравира, рекомбинантных аргининдеиминазы, РНКазы L и лактоферрина, а также биогенных наночастиц серебра или меди - препаратов, полученных с использованием современных молекулярно-биотехнологических методов.

COVID-19 pandemic caused by coronavirus SARS-CoV-2 affected virtually all life aspects in most countries and nations. During 2020 around 100 mln of Earth inhabitants contracted this morbid infection and 2 mln people died thereafter. It is natural therefore that many pharmaceutical companies around the globe have joined into the race aimed at elaboration of prophylactic antiviral vaccines. However, the option can not be ruled out that parenteral vaccines to counter rapidly mutating pandemic coronavirus may be designed hastily, neglecting due tests of remote side effects, so that in the long run they risk to be expelled from the marked due to doubtful safety and efficiency.

As a real alternative to traditional vaccination techniques the present mini-review has proposed application of intranasal adjuvant nano-vaccine. If necessary, this approach may be complemented with pharmacological inactivation of coronavirus under the impact of ribo-favipiravir, recombinant arginine deiminase, RNAse L or lactoferrin, as well as biogenic silver or copper nanoparticles - the preparations derived from up-to-date molecular biotechnological processes.

пандемия COVID-19вакцинацияхимиотерапиямодифицированный нуклеозидлактоферринрибонуклеазааргининдеиминазананочастицы серебра и медиCOVID-19 pandemicvaccinationchemotherapymodified nucleosidelactoferrinribonucleasearginine deiminasesilver and copper nanoparticlesReferencesCOVID-19 data repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University [Electronic resource]. - 2021. - Mode of access: https://github.com/CSSEGISandData/COVID-19. - Date of access: 07.03.2021.COVID-19 data repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, 2021. Available at: https://github.com/CSSEGISandData/COVID-19 (accessed 07.03.2021).SARS and MERS: recent insights into emerging coronaviruses / E. de Wit [et al.] // Nat. Rev. Microbiol. - 2016. -Vol. 14, N 8. - P 523-534. https://doi.org/10.1038/nrmicro.2016.81de Wit E., van Doremalen N., Falzarano D., Munster V. J. SARS and MERS: recent insights into emerging coronaviruses. Nature Reviews Microbiology, 2016, vol. 14, no. 8, pp. 523-534. https://doi.org/10.1038/nrmicro.2016.81Nano-based approach to combat eme^i^ viral (И1РАН virus) infection / R. G. Kerry [et al.] // Nanomed. Nanotechnol. Biol. Med. - 2019. - Vol. 18. - P 196-220. https://doi.org/10.1016/j.nano.2019.03.004Kerry R. G., Malik S., Redda Y. T., Sahoo S., Patra J. K., Majhi S. Nano-based approach to combat emerging viral (NIPAH virus) infection. Nanomedicine: Nanotechnology, Biology and Medicine, 2019, vol. 18, pp. 196–220. https://doi.org/10.1016/j.nano.2019.03.004Tyrrell, D. А. Cultivation of viruses from a high proportion of patients with colds / D. А. Tyrrell, M. L. Bynoe // Lancet. - 1966. - Vol. 289, N 7428. - P 76-77. https://doi.org/10.1016/s0140-6736(66)92364-6Tyrrell D. А., Bynoe M. L. Cultivation of viruses from a high proportion of patients with colds. Lancet, 1966, vol. 289, no. 7428, pp. 76-77. https://doi.org/10.1016/s0140-6736(66)92364-6Transmission electron microscopy imaging of SARS-CoV-2 / S. Prasad [et al.] // Indian J. Med. Res. - 2020. - Vol. 151, N 2-3. - P 241-243. https://doi.org/10.4103/ijmr.IJMR_577_20Prasad S., Potdar V., Cherian S., Abraham P., Basu А. Transmission electron microscopy imaging of SARS-CoV-2. Indian Journal of Medical Research, 2020, vol. 151, no. 2-3, pp. 241-243. https://doi.org/10.4103/ijmr.ijmr_577_20The proximal видт of SARS-CoV-2 / K. G. Andersen [et al.] // Nat. Med. - 2020. - Vol. 26, N 4. - P 450-452. https://doi.org/10.1038/s41591-020-0820-9Andersen K. G., Holmes E. C., Garry R. F. The proximal origin of SARS-CoV-2. Nature Medicine, 2020, vol. 26, no. 4, pp. 450-452. https://doi.org/10.1038/s41591-020-0820-9Repurposed drugs, molecular vaccines, immune-modulators, and nanotherapeutics to treat and prevent COVID-19 associated with SARS-CoV-2, a deadly nanovector / T. Dube [et al.] // Adv. Ther. - 2020. - Vol. 4, N 2. - АН. 2000172. https://doi.org/10.1002/adtp.202000172Dube T., Ghosh А., Mishra J., Kompella U. B., Panda J. J. Repurposed drugs, molecular vaccines, immune-modulators, and nanotherapeutics to treat and prevent COVID-19 associated with SARS-CoV-2, a deadly nanovector. Advanced Therapy, 2020, vol. 4, no. 2, art. 2000172. https://doi.org/10.1002/adtp.202000172SARS-CoV-2 life cycle: stages and inhibition targets [Electronic resource]. - 2020. - Mode of access: https://www.antibodies-online.com/resources/18/5410/sars-cov-2-life-cycle-stages-and-inhibition-targets. - Date ofaccess: 07.03.2021SARS-CoV-2 life cycle: stages and inhibition targets, 2020. Available at: https://www.antibodies-online.com/resources/18/5410/sars-cov-2-life-cycle-stages-and-inhibition-targets (accessed 07.03.2021).The COVID-19 vaccine development landscape / T. T. Le [et al.] // Nat. Rev. Drug Discov. - 2020. - Vol. 19, N 5. -P 305-306. https://doi.org/10.1038/d41573-020-00073-5Le T. T., Andreadakis /., Kumar А., Roman R. G., Tollefsen S., Saville M., Mayhew S. The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery, 2020, vol. 19, no. 5, pp. 305-306. https://doi.org/10.1038/d41573-020-00073-5The SARS-CoV-2 vaccine pipeline : an overview / W. H. Chen [et al.] // Curr. Trop. Med. Rep. - 2020. - Vol. 7, N 2. -P. 61-64. https://doi.org/10.1007/s40475-020-00201-6Chen W. H., Strych U., Hotez P. J., Bottazzi M. E. The SARS-CoV-2 vaccine pipeline: an overview. Current Tropical Medicine Reports, 2020, vol. 7, no. 2, pp. 61-64. https://doi.org/10.1007/s40475-020-00201-6The establishment of resident memory B cells in the lung requires local antigen encounter / S. R. Allie [et al.] // Nat. Immunol. - 2019. - Vol. 20, N 1. - P. 97-108. https://doi.org/10.1038/s41590-018-0260-6Allie S. R., Bradley J. E., Mudunuru U., Schultz M. D., Graf B. A., Lund F. E., Randall T. D. The establishment of resident memory B cells in the lung requires local antigen encounter. Nature Immunology, 2019, vol. 20, no. 1, pp. 97-108. https://doi.org/10.1038/s41590-018-0260-6Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes / A. Landi [et al.] // Vaccine. - 2017. - Vol. 35, N 50. - P. 6949-6956. https://doi.org/10.1016/j.vaccine.2017.10.072Landi A., Law J., Hockman D., Logan M., Crawford K., Chen C. [et al.]. Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes. Vaccine, 2017, vol. 35, no. 50, pp. 6949-6956. https://doi.org/10.1016/j.vaccine.2017.10.072Viromimetic STING agonist-loaded hollow polymeric nanoparticles for safe and effective vaccination against Middle East respiratory syndrome coronavirus / L. C. Lin [et al.] // Adv. Func. Mat. - 2019. - Vol. 29, N 28. - Art. 1807616. https://doi.org/10.1002/adfm.201807616Lin L. C., Huang C. Y., Yao B. Y., Lin J. C., Agrawal A., Algaissi A. [et al.]. Viromimetic STING agonist-loaded hollow polymeric nanoparticles for safe and effective vaccination against Middle East respiratory syndrome coronavirus. Advanced Functional Materials, 2019, vol. 29, no. 28, art. 1807616. https://doi.org/10.1002/adfm.201807616Создание рекомбинантного штамма Escherichia coli - продуцента диаденилатциклазы и ее использование для синтеза цикло-ди-АМФ / И. С. Казловский [и др.] // Вес. Нац. акад. навук Беларусi. Сер. бiял. навук. - 2015. - № 4. -С. 51-55.Kazlovskii I. S., Zinchenko A. I., Solov'eva A. V., Novikova O. N., Lomako Yu. V. Construction of Escherichia coli strain, producing di-adenylate cyclase and its application for cyclic di-AMP synthesis. Vestsi Natsyyanal'nai akademii navuk Belarusi. Seryya biyalagichnykh navuk = Proceedings of the National Academy of Sciences of Belarus. Biological series, 2015, no. 4, рр. 51-55 (in Russian).Optimization of formulations consisting of layered double hydroxide nanoparticles and small interfering RNA for efficient knockdown of the target gene / Y. Wu [et al.] // ACS Omega. - 2018. - Vol. 3, N 5. - P. 4871-4877. https://doi.org/10.1021/acsomega.8b00397Wu Y., Gu W., Chen C., Do S. T., Xu Z. P. Optimization of formulations consisting of layered double hydroxide nanoparticles and small interfering RNA for efficient knockdown of the target gene. ACS Omega, 2018, vol. 3, no. 5, pp. 4871-4877. https://doi.org/10.1021/acsomega.8b00397Intercalation and release of dinucleotides from a nanodimensional layered double hydroxide / A. S. Shchokolova [et al.] // Chemical and Biochemical Physics: A Systematic Approach to Experiments, Evaluation, and Modeling. - Oakville (Canada), 2016. - P. 317-327.Shchokolova A. S., Rymko A. N., Burko D. V., Kvach S. V., Zinchenko A. I. Intercalation and release of dinucleotides from a nanodimensional layered double hydroxide. Chemical and Biochemical Physics: A Systematic Approach to Experiments, Evaluation, and Modeling. Oakville (Canada), 2016, pp. 317-327.Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age / S. L. Block [et al.] // Vaccine. - 2008. - Vol. 26, N 38. - P. 4940-4946. https://doi.org/10.1016/j.vaccine.2008.07.013Block S. L., Yogev R., Hayden F. G., Ambrose C. S., Zeng W., Walker R. E. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine, 2008, vol. 26, no. 38, pp. 4940-4946. https://doi.org/10.1016/j.vaccine.2008.07.013Risk in vaccine research and development quantified / E. S. Pronker [et al.] // PLoS ONE. - 2013. - Vol. 8, N 3. -Art. e57755. https://doi.org/10.1371/journal.pone.0057755Pronker E. S., Weenen T. C., Commandeur H., Claassen E., Osterhaus A. Risk in vaccine research and development quantified. PLoS ONE, 2013, vol. 8, no. 3, e57755. https://doi.org/10.1371/journal.pone.0057755Immune response and possible therapeutics in COVID-19 / A. Dutta [et al.] // RSC Adv. - 2021. - Vol. 11. - P. 960-977. https://doi.org/10.1039/D0RA08901JDutta A., Roy A., Roy L., Chattopadhyay S., Chatterjee S. Immune response and possible therapeutics in COVID-19. RSC Advances, 2021, vol. 11, pp. 960-977. https://doi.org/10.1039/D0RA08901JRemdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial / Y. Wang [et al.] // Lancet. - 2020. - Vol. 395, N 10263. - P. 1569-1578. https://doi.org/10.1016/S0140-6736(20)31022-9Wang Y., Zhang D., Du G. Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial. Lancet, 2020, vol. 395, no. 10263, pp. 1569-1578. https://doi.org/10.1016/S0140-6736(20)31022-9Elfiky, A. A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study / A. A. Elfiky // Life Sci. - 2020. - Vol. 253. - Art. 117592. https://doi.org/10.1016/j.lfs.2020.117592Elfiky A. A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sciences, 2020, vol. 253, art. 117592. https://doi.org/10.1016/j.lfs.2020.117592Favipiravir (T-705), a novel viral RNA polymerase inhibitor / Y. Furuta [et al.] // Antiviral Res. - 2013. - Vol. 100, N 2. - P. 446-454. https://doi.org/10.1016/j.antiviral.2013.09.015Furuta Y., Gowen B. B., Takahashi K., Shiraki K., Smee D. F., Barnard D. L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Research, 2013, vol. 100, no. 2, pp. 446-454. https://doi.org/10.1016/j.antiviral.2013.09.015Experimental treatment with Favipiravir for COVID-19: an open-label control study / Q. Cai [et al.] // Engineering. - 2020. - Vol. 6, N 10. - P. 1192-1198. https://doi.org/10.1016/j.eng.2020.03.007Cai Q., Yang M., Liu D., Chen J., Shu D., Xia J., Liao X., Gu Y., Cai Q., Yang Y. Experimental treatment with Favi-piravir for COVID-19: an open-label control study. Engineering, 2020, vol. 6, no. 10, pp. 1192-1198. https://doi.org/10.1016/j.eng.2020.03.007de Clercq, E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections / E. de Clercq // Chem. Asian J. - 2019. - Vol. 14. - P. 3962-3968. https://doi.org/10.1002/asia.201900841de Clercq E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chemical Asian Journal, 2019, vol. 14, pp. 3962-3968. https://doi.org/10.1002/asia.201900841Uric acid elevation by favipiravir, an antiviral drug / E. Mishima [et al.] // Tohoku J. Exp. Med. - 2020. - Vol. 251, N 2. - P. 87-90. https://doi.org/10.1620/tjem.251.87Mishima E., Anzai N., Miyazaki M., Abe T. Uric acid elevation by favipiravir, an antiviral drug. Tohoku Journal of Experimental Medicine, 2020, vol. 251, no. 2, pp. 87-90. https://doi.org/10.1620/tjem.251.87Способ получения кинетинрибозида : пат. 20102 Респ. Беларусь / А. И. Береснев, С. В. Квач, Л. А. Ерошевская, А. И. Зинченко; заявитель Институт микробиологии НАН Беларуси. - № а20130261; заявл. 04.03.2013; опубл. 30.06.2016.Beresnev A. I., Kvach S. V., Eroshevskaya L. A., Zinchenko A. I. Method of producing kinetinriboside: patent of the Republic of Belarus, no. 20102, 2016 (in Russian).Ингибирование синтеза РНК и репродукции вируса клещевого энцефалита под действием рибонуклеазы / Р. И. Салганик [и др.] // Докл. АН СССР. - 1968. - Т. 180, № 6. - С. 1473-1475.Salganik R. I., Batalina T. A., Berdishevskaya L. S., Mosolov A. N. Inhibition of RNA synthesis and re production of tickencephalitis virus under the influence of ribonuclease. Doklady Akademii nauk SSSR [Scientific reports of the Academy of Sciences of USSR], 1968, vol. 180, no. 6, pp. 1473-1475 (in Russian).Ильинская, О. Н. Рибонуклеазы как противовирусные агенты / О. Н Ильинская, Р. Шах Махмуд // Молекуляр. биология. - 2014. - Т. 48, № 5. - С. 707-717.Il'inskaya O. N., Shakh Makhmud R. Ribonucleases as antiviral agents. Molekularnaya biologiya [Molecular biology], 2014, vol. 48, no. 5, pp. 707-717 (in Russian).Makarov, A. A. Cytotoxic ribonucleases: molecular weapons and their targets / A. A. Makarov, O. N. Ilinskaya // FEBS Lett. - 2003. - Vol. 540, N 1-3. - P. 15-20. https://doi.org/10.1016/s0014-5793(03)00225-4Makarov A. A., Ilinskaya O. N. Cytotoxic ribonucleases: molecular weapons and their targets. FEBS Letters, 2003, vol. 540, no. 1-3, pp. 15-20. https://doi.org/10.1016/s0014-5793(03)00225-4Severe outcomes among patients with coronavirus disease 2019 (COVID-19) United States, February 12-March 16, 2020 / S. Bialek [et al.] // MMWR. - 2020. - Vol. 69, N 12. - Р. 343-346. https://doi.org/10.15585/mmwr.mm6912e2Bialek S., Boundy E., Bowen V., Chow N., Cohn A., Dowling N., Ellington S., Gierke R., Hall A., MacNeil J. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) United States, February 12-March 16, 2020. Morbidity and Mortality Weekly Report, 2020, vol. 69, no. 12, pp. 343-346. https://doi.org/10.15585/mmwr.mm6912e2Molecular mechanisms for the adaptive switching between the OAS/RNase L and OASL/RIG-I pathways in birds and mammals / E. Rong [et al.] // Front. Immunol. - 2018. - Vol. 9. - Art. 1398. https://doi.org/10.3389/fimmu.2018.01398Rong E., Wang X., Chen H., Yang C., Hu J., Liu W., Wang Z., Chen X., Zheng H., Pu J. Molecular mechanisms for the adaptive switching between the OAS/RNase L and OASL/RIG-I pathways in birds and mammals. Frontiers in Immunology, 2018, vol. 9, art. 1398. https://doi.org/10.3389/fimmu.2018.01398Engineering of bacterial strain-producer of chimeric protein containing human annexin A5 and Escherichia coli adenosine deaminase / A. I. Zinchenko [et al.] // East. Eur. Sci. J. (Dusseldorf). - 2017. - N 4. - P. 5-11.Zinchenko A. I., Kvach S. V., Eroshevskaya L. A., Bulatovski A. B. Engineering of bacterial strain-producer of chimeric protein containing human annexin A5 and Escherichia coli adenosine deaminase. Eastern European Scientific Journal (Dusseldorf), 2017, no. 4, pp. 5-11.Arginine depletion as a therapeutic approach for patients with COVID-19 / J. M. Grimes [et al.] // Int. J. Infect. Dis. - 2021. - Vol. 102. - P. 566-570. https://doi.org/10.1016/j.ijid.2020.10.100Grimes J. M., Khan S., Badeaux M., Rao R. M., Rowlinson S. W., Carvajal R. D. Arginine depletion as a therapeutic approach for patients with COVID-19. International Journal of Infectious Diseases, 2021, vol. 102, pp. 566-570. https://doi.org/10.1016/j.ijid.2020.10.100Izzo, F. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis / F. Izzo, M. Montella, A. P. Orlando // J. Gastroenterol. Hepatol. - 2007. - Vol. 22, N 1. - P. 86-91. https://doi.org/10.1111/j.1440-1746.2006.04463.xIzzo F., Montella M., Orlando A. P. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. Journal of Gastroenterology and Hepatology, 2007, vol. 22, no. 1, pp. 86-91. https://doi.org/10.1111/j.1440-1746.2006.04463.xLactoferrin: a glycoprotein involved in immunomodulation, anticancer, and antimicrobial processes / Q. Rascon-Cruz [et al.] // Molecules. - 2021. - Vol. 26, N 1. - Art. 205. https://doi.org/10.3390/molecules26010205Rascon-Cruz Q., Espinoza-Sanchez E. A., Siqueiros-Cendon T. S., Nakamura-Bencomo S. I., Arevalo-Gallegos S., Iglesias-Figueroa B. F. Lactoferrin: a glycoprotein involved in immunomodulation, anticancer, and antimicrobial processes. Molecules, 2021, vol. 26, no. 1, art. 205. https://doi.org/10.3390/molecules26010205Novel coronavirus infection in hospitalized infants under 1 year of age in China / M. Wei [et al.] // JAMA. - 2020. -Vol. 323, N 13. - P. 1313-1314. https://doi.org/10.1001/jama.2020.2131Wei M., Yuan J., Liu Y., Fu T., Yu X., Zhang Z. J. Novel coronavirus infection in hospitalized infants under 1 year of age in China. JAMA, 2020, vol. 323, no. 13, pp. 1313-1314. https://doi.org/10.1001/jama.2020.2131The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators / H. M. Habib [et al.] // Biomed. Pharmacother. - 2021. - Vol. 136. - АгР 111228. https://doi.org/10.1016/j.biopha.2021.111228Habib H. M., Ibrahim S., Zaim A., Ibrahim W. H. The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators. Biomedicine and Pharmacotherapy, 2021, vol. 136, art. 111228. https://doi.org/10.1016/j.biopha.2021.111228Kim, J. The role of Iron metabolism in lung inflammation and injury / J. Kim, M. Wessling-Resnick // J. Allergy Ther. – 2012. – Vol. 3, N 4. https://doi.org/10.4172/2155-6121.S4-004 [Abstract].Kim J., Wessling-Resnick M. The role of Iron metabolism in lung inflammation and injury. Journal of Allergy and Therapy, 2012, vol. 3, no. 4. https://doi.org/10.4172/2155-6121.S4-004Cavezzi, А. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. А narrative review / А. Cavezzi, E. Troiani, S. Corrao // Clin. Pract. - 2020. - Vol. 10, N 2. - АгР. 1271. https://doi.org/10.4081/cp.2020.1271Cavezzi A., Troiani E., Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clinics and Practice, 2020, vol. 10, no. 2, art. 1271. https://doi.org/10.4081/cp.2020.1271The antiviral properties of human milk: a multitude of defence tools from mother nature / D. Morniroli [et al.] // Nutrients. - 2021. - Vol. 13, N 2. - АгР. 694. https://doi.org/10.3390/nu13020694Morniroli D., Consales A., Crippa B. L., Vizzari G., Ceroni F., Cerasani J., Colombo L, Mosca F., Gianni M. L. The antiviral properties of human milk: a multitude of defense tools from mother nature. Nutrients, 2021, vol. 13, no. 2, art. 694. https://doi.org/10.3390/nu13020694Krupinka, А. M. Clinical aspects of the use of lactoferrin in dentistry / А. M. Krupinka, Z. Bogucki // J. Oral Biosci. -2021. https://doi.org/10.1016/jjob.2021.02.005Krupinka A. M., Bogucki Z. Clinical aspects of the use of lactoferrin in dentistry. Journal of Oral Biosciences, 2021. https://doi.org/10.1016/j.job.2021.02.005Chang, R. Lactoferrin as potential preventative and adjunct treatment for COVID-19 / R. Chang, T. B. Ng, W. Z. Sun // Int. J. Antimicrob. Agents. – 2020. – Vol. 56, N 3. – Art. 106118. https://doi.org/10.1016/j.ijantimicag.2020.106118Chang R., Ng T. B., Sun W. Z. Lactoferrin as potential preventative and adjunct treatment for COVID-19. International Journal of Antimicrobial Agents, 2020, vol. 56, no. 3, art. 106118. https://doi.org/10.1016/j.ijantimicag.2020.106118Development of dairy herd of transgenic goats as biofactory for large-scale production of biologically active recombinant human lactoferrin / I. Semak [et al.] // Transgen. Res. - 2019. - Vol. 28. - P 465-478. https://doi.org/10.1007/s11248-019-00165-ySemak I., Budzevich A., Maliushkova E., Kuzniatsova V., Popkov N., Zalutsky I., Ivashkevich O. Development of dairy herd of transgenic goats as biofactory for large-scale production of biologically active recombinant human lactoferrin. Transgenic Research, 2019, vol. 28, pp. 465-478. https://doi.org/10.1007/s11248-019-00165-yПолучение рекомбинантного лактоферрина человека из молока коз-продуцентов и его физиологические эффекты / В. С. Лукашевич [и др.] // Докл. Нац. акад. наук Беларуси. - 2016. - Т. 60, № 1. - С. 72-81.Lukashevich V. S., Budevich A. I., Semak I. V., Kuznetsova V. N., Malyushkova E. V., Pyzh A. E. [et al.]. Production of recombinant human lactoferrin from the milk of goat-producers and its physiological effects. Doklady Natsional'noi akademii nauk Belarusi [Reports of the National Academy of Sciences of Belarus], 2016, vol. 60, no. 1, pp. 72-81 (in Russian).АН that glitters is not silver-a new look at microbiological and medical applications of silver nanoparticles / P Kowalczyk [et al.] // Int. J. Mol. Sci. - 2021. - Vol. 22, N 2. https://doi.org/10.3390/ijms22020854Kowalczyk P., Szymczak M., Maciejewska M., Laskowski L., Laskowska M., Ostaszewski R., Skiba G., Franiak-Pietryga I. All that glitters is not silver - a new look at microbiological and medical applications of silver nanoparticles. International Journal of Molecular Sciences, 2021, vol. 22, no. 2, art. 854. https://doi.org/10.3390/ijms22020854Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds / H. H. Lara [et al.] // J. Nanobiotechnol. -2011. - Vol. 9. - АгР. 30. https://doi.org/10.1186/1477-3155-9-30Lara H. H., Garza-Trevino E. N., Ixtepan-Turrent L., Singh D. K. Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. Journal of Nanobiotechnology, 2011, vol. 9, art. 30. https://doi.org/10.1186/1477-3155-9-30Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection / D. Morris [et al.] // Viruses. - 2019. - Vol. 11, N 8. - АгР. 732. https://doi.org/10.3390/v11080732Morris D., Ansar M., Speshock J., Ivanciuc T., Qu Y., Casola A., Garofalo R. P. Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection. Viruses, 2019, vol. 11, no. 8, art. 732. https://doi.org/10.3390/v11080732Efficient and quick inactivation of SARS coronavirus and other microbes exposed to the surfaces of some metal catalysts / J. Han [et al.] // Biomed. Environ. Sci. - 2005. - Vol. 18, N 3. - P. 176-180.Han J., Chen L., Duan S. M., Yang Q. X., Yang M., Gao C., Zhang B. Y., He H., Dong X. P. Efficient and quick inactivation of SARS coronavirus and other microbes exposed to the surfaces of some metal catalysts. Biomedical and Environmental Sciences, 2005, vol. 18, no. 3, pp. 176-180.Potent antiviral effect of silver nanoparticles on SARS-CoV-2 / S. S. Jeremiah [et al.] // Biochem. Biophys. Res. Commun. - 2020. - Vol. 533, N 1. - P 195-200. https://doi.org/10.1016/j.bbrc.2020.09.018Jeremiah S. S., Miyakawa K., Morita T., Yamaoka Y., Ryo A. Potent antiviral effect of silver nanoparticles on SARS-CoV-2. Biochemical and Biophysical Research Communications, 2020, vol. 533, no. 1, pp. 195-200. https://doi.org/10.1016/j.bbrc.2020.09.018Hati, S. Impact of thiol-disulfide balance on the binding of Covid-19 spike protein with angiotensin-converting enzyme 2 receptor / S. Hati, S. Bhattacharyya // ACS Omega. – 2020. – Vol. 5, N 26. – P. 16292–16298. https://doi.org/10.1021/acsomega.0c02125Hati S., Bhattacharyya S. Impact of thiol-disulfide balance on the binding of Covid-19 spike protein with angiotensin-converting enzyme 2 receptor. ACS Omega, 2020, vol. 5, no. 26, pp. 16292-16298. https://doi.org/10.1021/acsomega.0c02125Virucidal effect against coronavirus SARS-CoV-2 of a silver nanocluster/silica composite sputtered coating / C. Balagna [et al.] // Open Ceram. – 2020. – Vol. 1. – Art. 100006. https://doi.org/10.1016/j.oceram.2020.100006Balagna C., Perero S., Percivalle E., Nepita E. V., Ferraris M. Virucidal effect against coronavirus SARS-CoV-2 of a silver nanocluster/silica composite sputtered coating. Open Ceramics, 2020, vol. 1, art. 100006. https://doi.org/10.1016/j.oceram.2020.100006Green synthesis of metallic nanoparticles and their potential applications to treat cancer / D. Zhang [et al.] // Front. Chem. – 2020. – Vol. 8. – Art. 799. https://doi.org/10.3389/fchem.2020.00799Zhang D., Ma X. I., Gu Y., Huang H., Zhang G. W. Green synthesis of metallic nanoparticles and their potential applications to treat cancer. Frontiers in Chemistry, 2020, vol. 8, art. 799. https://doi.org/10.3389/fchem.2020.00799Синенок, Д. Н. Биохимическое получение наночастиц меди / Д. Н. Синенок, Л. Л. Биричевская, А. И. Зинченко // Сахаровские чтения 2017 г.: экол. проблемы XXI века : материалы 17-й Междунар. науч. конф., Минск, 18-19 мая 2017 г. / МГЭИ им. А. Д. Сахарова БГУ. - С. 219-220.Sinenok D. N., Birichevskaya L. L., Zinchenko A. I. Biochemical preparation of copper nanoparticles. Sakharovskie chteniya 2017 goda: ekologicheskie problemy XXI veka: materialy 17-i mezhdunarodnoi nauchnoi konferentsii (Minsk, 18-19 maya 2017 goda) [Sakharov Readings 2017: environmental problems of the 21st century: proceedings of the 17th International scientific conference (Minsk, May 18-19, 2017)]. Minsk, 2017, pp. 219-220 (in Russian).Synthesis and antimicrobial activity of monodisperse copper nanoparticles / T. Kruk [et al.] // Colloids Surf. B: Biointerfaces. - 2015. - Vol. 128. - P 17-22. https://doi.org/10.1016/j.colsurfb.2015.02.009Kruk T., Szczepanowicz K., Stefanska J., Socha R. P., Warszynski P. Synthesis and antimicrobial activity of monodisperse copper nanoparticles. Colloids and Surfaces B: Biointerfaces, 2015, vol. 128, pp. 17-22. https://doi.org/10.1016/j.colsurfb.2015.02.009

The authors declare that there are no conflicts of interest present.